Status:
NOT_YET_RECRUITING
D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia
Lead Sponsor:
Assiut University
Conditions:
AML, Adult
Eligibility:
All Genders
18-70 years
Brief Summary
1. The effect of D-index on the onset and severity of FN in AML patients. 2. Relationship between the c-D-index and duration of FN in AML patients. 3. Correlation between D-index and MDR. 4. Correlati...
Detailed Description
Acute myeloid leukemia (AML) is highly malignant neoplasm responsible for a large number of cancer-related deaths. It continuously shows 2 peaks in occurrence in early childhood and later adulthood. W...
Eligibility Criteria
Inclusion
- Adult Patients (≥18 years) newly diagnosed as acute myeloid leukemia according to WHO 2016 diagnostic criteria.
- Hematologic diagnosis of de novo AML.
- Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.
- Standard induction chemotherapy (7+3 regimen) or consolidation regimens (HiDAC).
Exclusion
- 1\) AML on top of other hematological disorders. 2) Acute promyelocytic leukemia. 3) Patients who received palliative care or low-intensity treatment. 4) Poor PS (≥3) at the time of diagnosis.
- \-
Key Trial Info
Start Date :
June 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06188182
Start Date
June 1 2024
End Date
June 1 2026
Last Update
January 3 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.